Research programme: fatty acid amide hydrolase inhibitors-Johnson & Johnson

Drug Profile

Research programme: fatty acid amide hydrolase inhibitors-Johnson & Johnson

Alternative Names: JNJ 28833155; JNJ-1661010

Latest Information Update: 03 Sep 2010

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Class Amides; Piperazines; Small molecules; Thiadiazoles
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Neuropathic pain

Most Recent Events

  • 26 Aug 2010 Preclinical development is ongoing in the US
  • 19 Nov 2008 Pharmacodynamics data from a preclinical trial in Neuropathic pain presented at the 38th Annual Meeting of the Society for Neuroscience (SfN-2008)
  • 10 Apr 2008 Preclinical trials in Neuropathic pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top